Abbott India Partners with Novo Nordisk to Launch Extensior for Diabetes
Filing Summary
Abbott India Limited has announced a strategic collaboration with Novo Nordisk India to launch Extensior, a brand of semaglutide (Ozempic), aimed at enhancing diabetes management in India. This partnership leverages Novo Nordisk’s expertise in GLP-1 receptor agonists and Abbott’s distribution network. Extensior will be marketed as an adjunct therapy for type 2 diabetes, offering benefits such as HbA1c reduction and cardiovascular risk mitigation. The product will be available in a FlexTouch Pen device. This initiative addresses India’s growing diabetes burden and aims to improve access to advanced diabetes therapies.
Abbott India Limited has entered into a strategic collaboration with Novo Nordisk India to launch Extensior, a brand of semaglutide (Ozempic), to enhance diabetes management in India. The partnership aims to broaden access to semaglutide, a GLP-1 receptor agonist, for individuals with type 2 diabetes. Extensior will be marketed as an adjunct to diet and exercise, providing benefits such as HbA1c reduction, weight-loss, and cardiovascular risk reduction.
The financial terms of the collaboration between Abbott and Novo Nordisk have not been disclosed in the filing. However, the agreement allows Abbott to commercialize semaglutide under the brand name Extensior. This initiative is part of Abbott’s expanding portfolio of diabetes solutions, aiming to improve access to high-quality, evidence-based therapies in India.
Operationally, Extensior is designed to offer comprehensive diabetes management benefits. It is recognized for its efficacy in reducing HbA1c levels and providing weight-loss benefits. The product is also noted for its ability to reduce the risk of cardiovascular and kidney events in individuals with type 2 diabetes. Extensior will be available in a FlexTouch Pen device, which allows for precise dosing in 0.25 mg, 0.5 mg, and 1 mg strengths.
The timeline for the availability of Extensior in India has not been specified in the filing. However, Abbott has indicated that the product will be introduced soon as part of its efforts to address the growing diabetes burden in the country. The collaboration aims to leverage Abbott’s distribution network to expand access to semaglutide beyond the regions currently served by Novo Nordisk.
The collaboration involves two key entities: Abbott India Limited and Novo Nordisk India. Abbott will be responsible for the commercialization of Extensior in India, utilizing its strong distribution network. Novo Nordisk, known for its scientific leadership in GLP-1 receptor agonists, will provide the semaglutide product. This partnership combines the strengths of both companies to enhance diabetes care in India.
In the context of the Indian market, this collaboration addresses a significant health challenge. India is experiencing a rapid increase in diabetes cases, with more than 100 million individuals currently living with the condition. The introduction of Extensior aims to improve access to advanced diabetes therapies, addressing the gap in detection and care. The collaboration also aligns with efforts to manage the long-term risks associated with type 2 diabetes, such as cardiovascular and kidney issues.
Novo Nordisk is a global healthcare company focused on defeating serious chronic diseases. The company is known for pioneering scientific breakthroughs and expanding access to its medicines. Its collaboration with Abbott aims to make semaglutide more accessible to individuals with type 2 diabetes in India.
Abbott India Limited is a leading healthcare company with a focus on life-changing technologies across diagnostics, medical devices, nutrition, and branded generic medicines. Established in 1910, Abbott is committed to meeting the healthcare needs of consumers, patients, and doctors throughout India, both in urban and rural areas.